Eviva Partners, a new nonprofit advancing medical evidence awareness, exposes Andrew Wakefield’s role in the “Manufacture of Evidence” before RFK’s confirmation hearings.

Eviva Partners, a new nonprofit promoting better understanding of medical evidence, exposes role of Andrew Wakefield in the “Manufacture of Evidence” leading up to Robert F. Kennedy’s Confirmation hearings

NEW YORK, NY — Eviva Partners, a pioneering healthcare initiative founded by physician-scientist Alex Morozov, announced its launch today with an innovative mission to address critical gaps in healthcare delivery through “evidence fluency” – a new framework for understanding and communicating medical evidence.

“The new US Administration is poised to have a dramatic impact on the integrity of scientific publications and medical evidence,” said Alex Morozov, CEO and Founder. “An investigation over the past several days reveals a role of Andrew Wakefield in the “Manufacture of Evidence” leading up to Robert F. Kennedy’s Confirmation hearings. Wakefield 30 years ago was paid by another anti-vaccine lawyer, Richard Barr, to manufacture a study through research fraud showing a link between vaccines and autism. History now repeats itself, except now the anti-vaccine lawyer, Kennedy, could become in charge of US science and medicine as a whole.”

Eviva Partners’s solution to this crisis is simple: “Evidence Fluency.”  The premise is that one key, previously overlooked factor underlies the current challenges of poor and unequal outcomes and rising costs in the U.S. healthcare system: insufficient “evidence fluency” among patients, providers, and other healthcare stakeholders.

Eviva Partners introduces the concept of “evidence fluency” as a solution to the current crisis and a path towards improving healthcare overall, defined as having four components:

  • Understanding the concept of evidence as distinct from “proof;” 

  • Ability to assess the strength of evidence;

  • Ability to detect manipulation;

  • Ability to discuss evidence with others.

Eviva Partners will focus on three areas:

  1. Pioneering deep characterization of care gaps (both underuse and overuse), starting in hematology-oncology care, at the state level;

  2. Developing a multi-pronged approach to increase evidence fluency through:

    • “Two-Eyed Seeing” methodology for bridging worldviews 

    • K-12 evidence curriculum 

    • A tool kit for patients and providers

  3. Creating state and federal policy proposals to improve healthcare transparency and quality, starting with protecting the integrity of scientific literature.

The organization has assembled a distinguished advisory council including Elder Albert Marshall of the Mi’kmaw Nation, creator of the “Two-Eyed Seeing” methodology; Stephan Lewandowsky, a leading cognitive scientist at the University of Bristol, and Kevin Wake, President of the Uriel E. Owens Sickle Cell Disease Association of the Midwest. 

“Our preliminary surveys show that only 16% of U.S. adults correctly understand the difference between evidence and proof, while 36% have never heard the word ‘evidence’ used in a medical context,” said Morozov. “By improving evidence fluency across the healthcare ecosystem, we can help close care gaps and ultimately improve health outcomes for all.”

Initial pilot studies will focus on sickle cell disease and cancer, where care gaps are high. In addition, K-12 evidence curriculum will be piloted. Once those are completed, the organization plans to launch a nationwide public awareness campaign to promote evidence fluency.

For more information about Eviva Partners, and to read Alex Morozov’s expose, “Robert F. Kennedy, Andrew Wakefield and The Manufacture of Evidence,” visit www.evivapartners.org, or follow Eviva Partners on Twitter, BlueSky, LinkedIn, Facebook and Instagram. 

Media Contact:

info@evivapartners.org

Alex Morozov

Alex Morozov is a physician, scientist and drug developer with a passion for improving health outcomes and reducing care gaps in every community around the world. He is the CEO and founder of Eviva Partners, a nonprofit promoting better understanding of evidence through education and behavioral science approaches for both patients and providers, while characterizing and monitoring improvement in care gaps (defined as both underuse and overuse).  

Alex obtained his undergraduate degree from MIT, followed by combined MD-PhD training at the Albert Einstein College of Medicine in New York. After internal medicine residency at Columbia-Presbyterian and medical oncology fellowship at Memorial Sloan-Kettering Cancer Center in New York, Alex was recruited by a friend to join the pharmaceutical industry. Over his 14-year drug development career, Alex has designed, conducted and overseen hundreds of clinical trials, leading to regulatory approval of several new cancer therapies by the FDA and other health authorities around the world. Following his interest in data and digital innovation, he led teams developing and implementing new technologies to accelerate clinical trials, address health equity, and improve outcomes for patients in clinical practice.

He is working on a book called “The Language of Evidence: Getting Well in a World Without Proof,” from which portions of this essay are adopted.

Previous
Previous

Eviva Partners is joining the StandUpForScience March in Washington, DC

Next
Next

Robert F. Kennedy Jr., Andrew Wakefield and The Manufacture of Evidence